ARL4C and colorectal carcinoma: Together, these results underscored ARL4C as a critical biomarker for predicting recurrence and distant metastasis in CRC patients undergoing oxaliplatin-based chemotherapy, highlighting its potential as a therapeutic target to overcome chemoresistance and metastasis.